KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $272.1 million.

  • Alnylam Pharmaceuticals' Share-based Compensation rose 136.25% to $108.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $368.2 million, marking a year-over-year increase of 65.55%. This contributed to the annual value of $272.1 million for FY2024, which is 22.74% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Share-based Compensation stood at $272.1 million for FY2024, which was up 22.74% from $221.7 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Share-based Compensation registered a high of $272.1 million during FY2024, and its lowest value of $139.9 million during FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Share-based Compensation had a median value of $230.6 million in 2022 and averaged $241.5 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Share-based Compensation fell by 20.00% in 2020 and then soared by 39.18% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Share-based Compensation (Yearly) stood at $139.9 million in 2020, then climbed by 18.48% to $165.7 million in 2021, then surged by 39.18% to $230.6 million in 2022, then decreased by 3.89% to $221.7 million in 2023, then grew by 22.74% to $272.1 million in 2024.